1 |
Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S, Zhou S, Xie Y, Li A, Cao W, Tang X. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. Int J Med Sci 2021;18:1456-64. [PMID: 33628103 DOI: 10.7150/ijms.51256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Chorfi L, Fercha A, Derouiche F, Sebihi FZ, Houhou D, Chorfi K, Bendjemana K. N-Acetyltransferase 2, Glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population. Xenobiotica 2022;:1-20. [PMID: 35138223 DOI: 10.1080/00498254.2022.2040642] [Reference Citation Analysis]
|
3 |
Mishra K, Shah A, Patel K, Ghosh K, Bharadva S. Seroprevalence of HBV, HCV and HIV-1 and Correlation with Molecular Markers among Multi-Transfused Thalassemia Patients in Western India. Mediterr J Hematol Infect Dis 2020;12:e2020038. [PMID: 32670516 DOI: 10.4084/MJHID.2020.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Karimi M, De Sanctis V. Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category? Acta Biomed 2020;91:50-6. [PMID: 32420925 DOI: 10.23750/abm.v91i2.9592] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
|
6 |
Kandi V, Vinjamuri SR, Tanikella BP. Hepatitis C Viral Infection Among Beta-Thalassemia Patients: A Study From the Centre for Excellence in Thalassemia and Other Blood Disorders. Cureus 2021;13:e16207. [PMID: 34367809 DOI: 10.7759/cureus.16207] [Reference Citation Analysis]
|